Skip to content
Hackensack UMC logo
  • GIVE NOW
  • 1-844-HMH-WELL
  • Find a Doctor
  • About
  • Location
  • Team
  • News
  • Services
  • Research
  • Donate

Clinical Trials

Find a DoctorOur LocationsAwards and Accreditation

Home  › Research  ›  Trials

Search for:

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)


A prospective, multinational, multi-center, phase 2, randomized, controlled, open-label study evaluating the efficacy, safety, tolerability and pharmacokinetics of sig12d-loder in the treatment of patients with unresectable locally advanced pancreatic cancer when used in conjunction with standard chemotherapy (gemcitabine+nab-paclitaxel) versus chemotherapy (gemcitabine+nab-paclitaxel) alone


A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma


View all types of trials

Types of Cancer / Trials

  • All
  • Breast
  • Breast-Surgical Oncology
  • Gastrointestinal
  • Genito-Urinary
  • Gynecologic
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Neuro-oncology
  • Phase 1
  • Phase 1 (GI)
  • Phase 1 (L)
  • Phase 1 (Thoracic)
  • Skin and Soft Tissue
  • Thoracic (Lung)
  • Transplant

Recently Added Trials

  • Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
  • MERCK MK7902-001-01 A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
  • IST-2015-100730-Phase I Study of Carfilzomib-based Chemotherapy mobilization for autologous stem cell transplantation in multiple Myeloma
  • A Phase II, Randomized, Open-label Platform Study of Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
  • A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with Selected FGFR Gene Alterations

© 2019 Hackensack Meridian Health

  • About Us
  • Careers
  • Classes & Events
  • Contact Us
  • Financial Practices
  • Patients & Visitors
  • Privacy
  • Terms & Conditions